Senior Manager, Medical Science Liaison, Japan

About the role

We are seeking a highly motivated and experienced professional to join our team as a Medical Science Liaison (MSL). Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Reporting to JP Regional Medical Science Liaison (JPR MSL), MSLs are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved in various phases of product development. The individual will collaborate with stakeholders within medical affairs and across the organization, including but not limited to Clinical Development, Commercial, Program Management, Clinical Operations, and Compliance teams. The ideal candidate is an effective communicator, driven, detail-oriented, proactive, and a skilled collaborator.

Responsibilities

• Support the implementation and execution of the Medical Affairs strategy and tactical plans for assigned products and therapeutic areas, tailored to Japan.
• Establish and maintain trusted scientific relationships with key opinion leaders (KOLs), investigators, and healthcare professionals across Japan.
• Provide medical oversight and scientific input to cross-functional teams, ensuring alignment with regulatory and compliance standards.
• Contribute to medical input in promotional and non-promotional materials, internal training, and advisory boards.
• Plan and execute medical meetings, education, symposia, and congress participation to enhance scientific visibility.
• Support investigator-initiated trials and local clinical research activities in collaboration with global and regional teams.
• Monitor the competitive and scientific landscape to inform internal strategy and provide actionable medical insights.
• Partner with HEOR and market access to develop real-world evidence and outcomes research projects.
• Ensure compliance with data privacy regulations (Japan).
• Collaborate closely with Clinical Operations and CROs, including site selection, Site Initiation Visits, and investigator engagement.
• Provide scientific review to ensure medical accuracy in materials developed by cross‑functional teams, including non‑promotional content and internal scientific training.
• Required Skills, Experience and Education:
• Minimum 5 years of experience in Medical Affairs or related functions in the pharmaceutical or biotech industry.
• Strong understanding of oncology clinical development, evidence generation, and treatment landscape.
• Proven ability to analyze and synthesize scientific information effectively.
• Experience engaging with healthcare professionals, academic researchers, and medical societies with compliance rules.
• Excellent interpersonal, organizational, and presentation skills.
• Fluency in Japanese and English (business level).
• Ability to work effectively in a matrixed, cross-functional, and multicultural environment.
• Willingness to travel up to 70% of time.
• Preferred Skills:
• Advanced scientific or medical degrees (MD, RPh, Ns, PhD, MPh, or MS) preferred.
• Experience leading or supporting investigator-initiated or real-world evidence studies.
• Track record in publication planning, congress presentations, and scientific communications.
• We are aware of recent recruitment s

Benefits

Additional Information

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

Your Match

How well this role fits your profile.

Company Intel

What employees say

Worked at revolutionmedicines? Share your experience